Runben Biotechnology Co Ltd. Class A

Runben Biotechnology Co Ltd. Class A

SSSE:603193
17.34
CNY
+0.40
(+2.36%)
0.86EPS
23.51P/E
8.19BMarket Cap
Mar 03Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.47
1.45
1.74
2.51
2.92
3.25
3.83
4.23
Basic EPS, GAAP
0.7
0.31
0.36
0.47
0.64
0.74
0.78
0.86
Free Cash Flow per Basic Share
0.85
0.09
-0.04
0.37
0.68
0.45
0.46
- -
Dividend per Share
- -
- -
0.09
0.01
- -
0.34
0.44
0.29
Book Value per Share
1.33
2.43
1.63
2.1
4.75
5.14
5.49
5.69
Tangible Book Value per Share
1.13
2.23
1.58
2.04
4.7
5.01
5.27
5.48
Basic Weighted Avg Shares
51
306
335
341
353
406
403
405
Sales/Revenue/Turnover
279
443
582
856
1,033
1,318
1,545
1,713
Operating Margin (%)
17.77
24.81
23.63
21.06
24.3
23.65
21.61
21.87
Depreciation Expense
8
8
11
20
22
21
22
- -
Net Income, GAAP
36
95
121
160
226
300
315
349
Effective Tax Rate (%)
14.54
14.09
14.82
14.99
15.64
14.73
13.18
11.88
Profit Margin (%)
12.8
21.39
20.72
18.69
21.88
22.77
20.36
20.34
Working Capital
49
118
269
413
1,621
1,458
1,527
1,530
LT Debt
- -
- -
8
5
2
1
- -
- -
Total Equity
137
250
562
723
1,921
2,080
2,221
2,303
Return on Invested Capital (%)
- -
48.6
28.85
23.57
16.52
14.56
14.44
15.39
Return on Capital (%)
- -
48.88
29.69
24.69
17.04
14.98
14.61
15.56
Return on Common Equity (%)
- -
48.88
29.72
24.92
17.1
15
14.62
15.57

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
1
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
405
405
405
Market Capitalization
8,998
7,505
8,193

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,696
1,795
1,647
Cash, Cash Equivalents & STI
1,142
1,510
1,443
Accounts Receivable, Net
22
93
33
Inventories
187
161
139
Total Current Liabilities
154
205
117
Payables & Accruals
- -
- -
- -
ST Debt
1
1
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
66.82%
6.75%
Free Cash Flow
- -
-221.46%
2.41%
Net Income, GAAP
- -
27.77%
4.78%
Sales/Revenue/Turnover
- -
28.8%
17.19%
Total Cash Common Dividend
- -
- -
29.52%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
167
577
293
281
1,318
2025
240
655
- -
307
1,545
2026
267
787
352
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.36
0.2
0.1
0.74
2025
0.11
0.35
- -
0.12
0.78
2026
0.13
0.43
0.19
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.17
0.34
2025
- -
- -
- -
0.01
0.44
2026
- -
- -
0.28
- -
- -

Company Description

CEO
Guai Qin Zhao
Full Time Employees
1,018
Sector
Consumer non-durables
Industry
Household/Personal care
Address
No. 3, Xinzhuang 5th Road Guangzhou GD China 510627
IPO Date
Oct 17, 2023
Website
runben.com
Business
Runben Biotechnology Co., Ltd. (SSE: 603193) engages primarily in the research, development, production, and sale of high-end biological reagents and related products for life sciences and medical diagnostics. The company offers core products including nucleic acid extraction and purification reagents, PCR master mixes, reverse transcription kits, real-time PCR detection kits, protein purification reagents, cell culture media and sera, transfection reagents, and fluorescent quantitative PCR instruments; it also provides customized services for molecular diagnostics and biological research consumables. Runben Biotechnology serves research institutions, pharmaceutical companies, clinical laboratories, and biotechnology firms across China and select international markets, with manufacturing and distribution operations concentrated in the Asia-Pacific region. Founded in 2007 and headquartered in Guangzhou, China, the company operates as an independent entity listed on the Shanghai Stock Exchange since 2020. In recent developments within the last two years, Runben Biotechnology expanded its product portfolio through the launch of advanced real-time PCR systems and automated nucleic acid extractors tailored for high-throughput clinical testing, amid growing demand post-pandemic; it also formed strategic partnerships with domestic diagnostic firms to enhance its molecular diagnostics offerings and invested in capacity expansions at its Guangdong facilities to support increased export activities to Southeast Asia.